7 Needs context
Berberine is clinically equivalent to metformin in lowering HbA1c and reducing postprandial blood glucose in pre-diabetics and diabetics.
"it does lower your A1C. It does help reduce blood sugars after eating. Uh very similar results." (said at 0:13:40)
Small randomized clinical trials have found that berberine significantly lowers HbA1c, fasting plasma glucose, and postprandial blood glucose in patients with type 2 diabetes, producing reductions comparable in magnitude to metformin monotherapy (such as berberine 500 mg three times daily). However, systematic reviews emphasize that the evidence base consists of small trials with low methodological quality, limited sample sizes, and unclear risk of bias. While preliminary data demonstrate comparable glycemic effects in short-term pilot studies, larger, high-quality randomized controlled trials are needed to firmly establish clinical equivalence.
- supports: Efficacy of berberine in patients with type 2 diabetes mellitus. (Metabolism: clinical and experimental 2008) · cited 785x in the literature
"In study A, 36 adults with newly diagnosed type 2 diabetes mellitus were randomly assigned to treatment with berberine or metformin (0.5 g 3 times a day) in a 3-month trial. The hypoglycemic effect of berberine was similar to that of metformin. Significant decreases in hemoglobin A1c (from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01), fasting blood glucose (from 10.6+/-0.9 mmol/L to 6.9+/-0.5 mmol/L, P<.01), postprandial blood glucose (from 19.8+/-1.7 to 11.1+/-0.9 mmol/L, P<.01), and plasma triglycerides (from 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05) were observed in the berberine group." (abstract, results, passage verified)
pubmedfull study (doi) - context: Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysi… (Evidence-based complementary and alternative medicine : eCAM 2012) · cited 222x in the literature
"Compared with oral hypoglycaemics including metformin, glipizide, or rosiglitazone, berberine did not demonstrate a significantly better glycaemic control but showed a mild antidyslipidemic effect... However, the evidence of berberine for treating T2DM should be carefully interpreted due to the low methodological quality, small sample size, limited number of trials, and unidentified risks of bias." (abstract, results and conclusions)
pubmedfull study (doi)
Consuming refined carbohydrates, alcohol, and tea depletes bodily stores of vitamin B1.
"And when you consume more refined carbs, you you use up your B1. When you drink alcohol, you use up your B1. When you consume more tea, you use up a lot of your stored B1." (said at 0:16:54)
The statement contains a mixture of established metabolic principles and overstated mechanisms across the three substances. Alcohol intake is well-established to induce thiamine (vitamin B1) deficiency by impairing intestinal absorption, reducing hepatic storage, and interfering with its phosphorylation and utilization. Diets high in refined carbohydrates increase metabolic demand for thiamine, as thiamine pyrophosphate serves as an essential cofactor for key glucose-utilizing enzymes (such as pyruvate dehydrogenase, transketolase, and alpha-ketoglutarate dehydrogenase), which can precipitate deficiency if intake does not match demand. However, tea does not deplete or 'use up' endogenous bodily stores of thiamine; rather, tannins and polyphenolic compounds in tea act as anti-thiamine factors in the digestive tract by binding to or modifying dietary thiamine, thereby inhibiting its intestinal absorption when consumed concurrently with meals.
Dietary glutamine helps heal and repair the intestinal lining.
"carnivore which actually are very very successful at kind of healing the gut because it's high in glutamine which actually can help heal the gut." (said at 0:12:19)
Glutamine is the primary metabolic fuel for enterocytes and plays a well-established physiological role in maintaining intestinal epithelial integrity and tight junction regulation. In clinical trials, oral glutamine supplementation has demonstrated improvements in intestinal permeability in specific conditions, such as post-infectious irritable bowel syndrome with baseline hyperpermeability, and meta-analyses suggest reductions in permeability at higher supplemental doses (>30 g/day). However, systematic reviews in broader clinical populations, such as inflammatory bowel disease, have shown mixed or null therapeutic benefits on mucosal healing, and there is no clinical evidence demonstrating that dietary glutamine from specific regimens (such as a carnivore diet) heals the gut.
- supports: Glutamine and the regulation of intestinal permeability: from bench to bedside. (Current opinion in clinical nutrition and metabolic care 2017) · cited 80x in the literature
"Glutamine is a major nutrient to maintain intestinal barrier function in animals and humans. Depletion of glutamine results in villus atrophy, decreased expression of tight junction proteins and increased intestinal permeability. Moreover, glutamine supplementation can improve gut barrier function in several experimental conditions of injury and in some clinical situations." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious ir… (Gut 2019) · cited 188x in the literature
"In patients with IBS-D with intestinal hyperpermeability following an enteric infection, oral dietary glutamine supplements dramatically and safely reduced all major IBS-related endpoints." (abstract, conclusions, passage verified)
pubmedfull study (doi) - partial: Effects of glutamine supplementation on inflammatory bowel disease: A systematic review of… (Clinical nutrition ESPEN 2021) · cited 40x in the literature
"The findings obtained through this systematic review indicate that glutamine supplementation has no effect on disease course, anthropometric measurements, intestinal permeability and morphology, disease activity, intestinal symptoms, biochemical parameters, oxidative stress and inflammation markers in patients with IBD" (abstract, conclusions, passage verified)
pubmedfull study (doi) - partial: A systematic review and meta-analysis of clinical trials on the effects of glutamine suppl… (Amino acids 2024) · cited 19x in the literature
"Overall, glutamine supplementation did not significantly affect intestinal permeability (WMD: -0.00, 95% CI -0.04, 0.03). Subgroup analysis showed a significant reduction in intestinal permeability with doses over 30g/day (WMD: -0.01, 95% CI -0.10, -0.08)." (abstract, results, passage verified)
pubmedfull study (doi)
Insulin resistance is mechanistically linked to sleep apnea by promoting fat deposition in the pharynx and upper airway.
"Sleep apnea has been linked to something called insulin resistance... Well, the insulin starts making more and more and more and more and more with insulin resistance and then uh one of the effects is sleep apnea. So you just you it starts creating fat in the back of the throat and you you're breathing, you snore, you have you can't get air" (said at 0:25:03)
Obstructive sleep apnea (OSA), obesity, and insulin resistance are closely linked, but the speaker simplifies and partially reverses the primary causal mechanisms. Anatomical upper airway narrowing—caused by fatty tissue deposition in the pharyngeal walls and tongue—is primarily driven by overall adiposity and obesity rather than being a direct isolated consequence of hyperinsulinemia. Furthermore, evidence indicates a strong bidirectional relationship in which sleep apnea and intermittent hypoxia exacerbate insulin resistance and metabolic dysfunction, rather than insulin resistance acting solely as the upstream cause of throat fat accumulation.
- context: Abdominal fat and sleep apnea: the chicken or the egg? (Diabetes care 2008) · cited 40x in the literature
"There are several mechanisms responsible for the increased risk of OSA with obesity. These include reduced pharyngeal lumen size due to fatty tissue within the airway or in its lateral walls, decreased upper airway muscle protective force due to fatty deposits in the muscle, and reduced upper airway size secondary to mass effect of the large abdomen on the chest wall and tracheal traction." (abstract, results, passage verified)
pubmedfull study (doi) - context: Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. (Journal of the American College of Cardiology 2013) · cited 881x in the literature
"Moreover, findings from animal models and patients with OSA show that intermittent hypoxia exacerbates the metabolic dysfunction of obesity, augmenting insulin resistance and nonalcoholic fatty liver disease." (abstract, results, passage verified)
pubmedfull study (doi) - context: Sleep Apnea, Obesity, and Disturbed Glucose Homeostasis: Epidemiologic Evidence, Biologic … (Current obesity reports 2020) · cited 94x in the literature
"The mechanisms hypothesized to be involved in this complex interplay are the following: (1) "direct weight-dependent" mechanisms, according to which fat excess compromises respiratory mechanics, and (2) "indirect weight-dependent" mechanisms such as hyperglycemia, insulin resistance and secondary hyperinsulinemia, leptin resistance and other hormonal dysregulations frequently found in subjects with obesity, type 2 diabetes, and/or sleep disorders." (abstract, results, passage verified)
pubmedfull study (doi)
Uric acid levels rise during the initial adaptation phase of entering ketosis.
"So when you go on keto, it's possible that your uric acid will go up initially in the first phase, but then it goes down. But it's part of the adaptation process." (said at 0:44:44)
The speaker's statement that uric acid may rise transiently during initial ketogenic adaptation before returning to baseline is biologically plausible and documented during acute ketosis (where circulating ketone bodies like beta-hydroxybutyrate compete with uric acid for renal tubular secretion). However, systematic reviews and meta-analyses of clinical trials evaluating ketogenic diets over several weeks find that overall serum uric acid levels do not show sustained or significant net increases compared to baseline across study endpoints.
Gout is caused by fructose, and the theory that dietary protein causes gout has been debunked.
"But usually gout comes from the fructose. And in gout, I've seen so many people with gout go on low-carb and get rid of their gout. So, this whole theory that gout comes from eating protein has been debunked long ago." (said at 0:45:00)
The claim contains accurate elements but requires important qualification. Fructose and sugar-sweetened beverage consumption are indeed established risk factors associated with an increased risk of incident gout (PMID 18244959, PMID 21068145); however, fructose is only one contributing factor among major causes such as genetic variants, impaired renal urate clearance, alcohol consumption, and obesity. Regarding protein, prospective cohort research confirms that total dietary protein intake is not associated with an increased risk of gout (PMID 15014182). However, stating that protein's link to gout has been entirely debunked is incomplete: specific purine-dense animal proteins, namely red meat and seafood, remain well-documented risk factors for hyperuricemia and incident gout (PMID 15014182).
- partial: Purine-rich foods, dairy and protein intake, and the risk of gout in men. (The New England journal of medicine 2004) · cited 1191x in the literature
"Higher levels of meat and seafood consumption are associated with an increased risk of gout, whereas a higher level of consumption of dairy products is associated with a decreased risk." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. (BMJ (Clinical research ed.) 2008) · cited 583x in the literature
"Prospective data suggest that consumption of sugar sweetened soft drinks and fructose is strongly associated with an increased risk of gout in men." (abstract, conclusions, passage verified)
pubmedfull study (doi) - context: Fructose-rich beverages and risk of gout in women. (JAMA 2010) · cited 316x in the literature
"Among this cohort of women, consumption of fructose-rich beverages is associated with an increased risk of incident gout, although the contribution of these beverages to the risk of gout in the population is likely modest given the low incidence rate among women." (abstract, conclusions, passage verified)
pubmedfull study (doi)
There are at least 31 distinct diseases causally or pathophysiologically connected to insulin resistance.
"If it works on insulin resistance, then it obviously is going to work on everything connected to that, and there's at least 31 different diseases connected with insulin resistance." (said at 0:35:20)
Extensive epidemiological and mechanistic research establishes that insulin resistance is pathophysiologically linked to a broad spectrum of chronic diseases spanning multiple organ systems—including type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease (MASLD), polycystic ovary syndrome (PCOS), Alzheimer's disease, and multiple malignancies. However, the specific figure of 'at least 31 distinct diseases' represents an informal or popular categorization rather than a standardized epidemiological or clinical classification. Furthermore, while improving insulin sensitivity can ameliorate many metabolic risk factors, asserting that treating insulin resistance will 'obviously work on everything connected to that' overstates the evidence, as these diseases are multifactorial conditions with independent genetic, environmental, and non-metabolic drivers.
- context: A Comprehensive Review of Pathophysiological Link Between Non-alcoholic Fatty Liver Diseas… (Cureus 2024) · cited 11x in the literature
"The review indicates that IR contributes to hepatic lipid accumulation through increased lipolysis, elevated free fatty acid flux, and impaired fatty acid oxidation, while MetS exacerbates the condition by promoting visceral adiposity, chronic inflammation, and impaired lipid metabolism." (abstract, results, passage verified)
pubmedfull study (doi) - context: Metabolic Syndrome in Focus: Emerging Causes, New Diagnostic Approaches and Criteria, and … (Cureus 2026) · cited 3x in the literature
"Metabolic syndrome (MetS) is a complex cluster of metabolic abnormalities, including central obesity, hypertension, dyslipidemia, insulin resistance, and impaired glucose metabolism. Growing evidence indicates that MetS is not only a major risk factor for cardiovascular disease but is also strongly associated with the development and progression of various malignancies." (abstract, results, passage verified)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.